Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Executive Summary
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.
You may also be interested in...
Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.
Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review
Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.